# REYVOW — FDA application NDA211280

Informational only - not investment advice.

Application NDA211280 · type NDA · FDA status: approved · original approval 2019-10-11

Listed sponsor: ELI LILLY AND CO · [LLY company profile](/company/LLY/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | REYVOW | LASMIDITAN SUCCINATE | TABLET | ORAL | EQ 50MG BASE | Discontinued | not listed | Yes |
| 002 | REYVOW | LASMIDITAN SUCCINATE | TABLET | ORAL | EQ 100MG BASE | Discontinued | not listed | Yes |
| 003 | REYVOW | LASMIDITAN SUCCINATE | TABLET | ORAL | EQ 200MG BASE | Discontinued | not listed | Yes |

## Orange Book patent and exclusivity listings

- Patent 7423050, product 001; listed patent expiry date: 2028-02-17.
- Patent 7423050, product 002; listed patent expiry date: 2028-02-17.
- Patent 7423050, product 003; listed patent expiry date: 2028-02-17.
- Patent 12257246, product 001; listed patent expiry date: 2030-07-07.
- Patent 12257246, product 002; listed patent expiry date: 2030-07-07.
- Patent 12257246, product 003; listed patent expiry date: 2030-07-07.
- Patent 11053214, product 001; listed patent expiry date: 2037-12-05.
- Patent 11053214, product 002; listed patent expiry date: 2037-12-05.
- Patent 11053214, product 003; listed patent expiry date: 2037-12-05.
- Patent 12071423, product 001; listed patent expiry date: 2040-07-06.
- Patent 12071423, product 002; listed patent expiry date: 2040-07-06.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- LASMIDITAN · UNII 760I9WM792 · [lmmol compound XEDHVZKDSYZQBF-UHFFFAOYSA-N](https://lmmol.com/compound/XEDHVZKDSYZQBF-UHFFFAOYSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/LLY/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211280. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.